To assess the efficacy of percutaneous minocycline hydrochloride sclerotherapy in symptomatic hepatic cysts.
From November 1992 to June 1994, seven of eight consecutive adults with large symptomatic ...hepatic cysts (diameter, 55-130 mm) were treated with a single intracystic injection of minocycline hydrochloride in an ambulatory procedure. Five patients had a solitary cyst, and two had polycystic liver disease. The target cyst was punctured under ultrasound guidance and local anesthesia with a 22-gauge Chiba needle. Half of the cyst content was aspirated before injection of 100-500 mg of minocycline hydrochloride diluted in 5-25 mL of saline. The minocycline hydrochloride was left in the cyst at the end of the procedure.
After a mean follow-up of 28 months (range, 24-42 months), all five patients with solitary cysts were asymptomatic and four had documented complete cyst regression; the two patients with multiple hepatic cysts showed only transient clinical improvement.
Single-shot injection of minocycline hydrochloride is an effective treatment for symptomatic solitary hepatic cysts but is less effective in polycystic liver disease.
To evaluate a magnetic resonance (MR) imaging contrast agent for tumor detection based on paramagnetic nonionic vesicles (niosomes) bearing polyethylene glycol (PEG) and glucose conjugates for the ...targeting of overexpressed glucose receptors.
Four gadobenate dimeglumine-loaded niosome preparations including nonconjugated niosomes, niosomes bearing glucose conjugates (N-palmitoyl glucosamine NPG), niosomes bearing PEG 4400, and niosomes bearing both PEG and NPG were tested. In vitro cellular uptake was measured at electron paramagnetic resonance (EPR) after incubation with human prostate carcinoma, PC3, cells. In vivo distribution was studied at MR imaging 6, 12, and 24 hours after injection, with assessment of tumor, brain, liver, and muscle signal intensity (SI) in 49 mice bearing PC3 cells. Efficiency of targeted contrast agents was assessed with tumor-to-muscle contrast-to-noise ratio (CNR). Testing for differences was performed with analysis of variance followed by a posteriori Fisher test.
In vitro, gadolinium could be detected at EPR only in cell pellets incubated with niosomes bearing glucose conjugates or niosomes bearing both glucose conjugates and PEG (4.9. 10(-15) and 4.5. 10(-15) mol gadolinium per PC3 cell). In vivo, marked predominant tumor enhancement was demonstrated 24 hours after injection of glycosylated PEG niosomes (P <.01); no significant differences were observed following injection of nonconjugated niosomes, glycosylated niosomes, or PEG 4400 niosomes. Twenty-four hours after injection, sole presence of NPG or PEG 4400 on the surface of the niosome led to higher tumor-to-muscle CNR than that observed after injection of nonconjugated niosomes (CNR of 3.3 +/- 0.7 SD, 3.4 +/- 2.2, and 0 +/- 1.9). Combination of NPG and PEG led to even higher tumor-to-muscle CNR (6.3 +/- 2.2).
Combination of PEG and glucose conjugates on the surface of niosomes significantly improved tumor targeting of an encapsulated paramagnetic agent assessed with MR imaging in a human carcinoma xenograft model.
Capillary leakage of a macromolecular contrast agent, Carboxymethyl Dextran-Gd-DTPA (CMD-Gd-DTPA) was characterized in a highly permeable system, the liver, to assess its potential as a blood pool ...marker. Its elimination kinetics in hepatic lymph were compared in nephrectomized rabbits with that of a tracer of extra cellular fluid space, Gd-DOTA. Four parameters were defined: volume of distribution, normalized initial leakage rate (ILR
n), maximum ratio of lymph and plasma concentrations (max
C
L
C
P
), and the time to obtain this maximum ratio. The effect of this leakage was studied on MR images by comparing liver contrast enhancement after injection and after almost total removal of the contrast agent from the blood by exchange transfusion. Capillary leakage of CMD-Gd-DTPA was detected in lymph. Compared to Gd-DOTA, it was slower (ILR
n = 0.36 10
−5 l min
−1 for CMD-Gd-DTPA and ILR
n = 2.6 10
−5 l min
−1 for Gd-DOTA), less abundant (max
C
L
C
P
was 80% for CMD-Gd-DTPA and 100% for Gd-DOTA). Liver enhancement remained stable, which indicated that the leakage did not modify the enhancement induced by the intravascular fraction of the contrast agent. These results obtained in a highly permeable capillary model indicate that this agent can be used as a selective blood pool enhancer.
PDF
